A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 2335
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : mCRC
Long Form : metastatic colorectal cancer
No. Year Title Co-occurring Abbreviation
2020 A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study. DLTs, RE-OPEN
2020 Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802). ORR
2020 CD276-Positive Circulating Endothelial Cells Do Not Predict Response to Systemic Therapy in Advanced Colorectal Cancer. AUC
2020 Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer. SCNAs
2020 Circulating tumor cell free DNA from plasma and urine in the clinical management of colorectal cancer. ---
2020 Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients. CI, FP, HR, IRI, MC, NMC, OS, OXA
2020 Colorectal cancer-derived exosomal miR-106b-3p promotes metastasis by down-regulating DLC-1 expression. DLC-1, EMT
2020 Comparative Study of NGS Platform Ion Torrent Personal Genome Machine and Therascreen Rotor-Gene Q for the Detection of Somatic Variants in Cancer. NGS, NSCLC, WT
2020 Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer. RI-FOLFOXIRI
10  2020 Comparison of efficacy and safety for patients with beyond second line treated metastatic colorectal cancer: a network meta-analysis of randomized controlled trials. RCTs
11  2020 Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer. ICERs, QALYs, WT
12  2020 Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of RAS wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study. ICERs, KM, LYs, QALYs, WT
13  2020 Cost-Effectiveness of RAS Genetic Testing Strategies in Patients With Metastatic Colorectal Cancer: A Systematic Review. EGFR
14  2020 D-Dimer level was associated with prognosis in metastatic colorectal cancer: A Chinese patients based cohort study. ---
15  2020 Different variables predict the outcome of patients with synchronous versus metachronous metastases of colorectal cancer. MMs
16  2020 Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. aHR, DLL, OS, STL
17  2020 Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram. ---
18  2020 Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib. CTC, OS, PD
19  2020 Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer. ---
20  2020 Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions. ACT, BTC, ICIs, PD-1
21  2020 Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer. DCR, FVIII, OS, PFS, VTE
22  2020 hERG1 and HIF-2alpha Behave as Biomarkers of Positive Response to Bevacizumab in Metastatic Colorectal Cancer Patients. aHIF-2alpha, PFS
23  2020 Impact of KRAS mutation status on outcomes of metastatic colorectal cancer treated with anti-angiogenic agents: a meta-analysis. OS, PFS, RCTs
24  2020 Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Post Hoc Analysis of the VELOUR Trial. OS, PFS, PlGF
25  2020 Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. CAPRI-GOIM, EGFR, MoAbs
26  2020 KLF4 p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer. ctDNA, EGFR, KLF4
27  2020 Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial. BMI, CAP-B, CAPOX-B, CT, SMI
28  2020 Magnitude of advantage in tumor response contributes to a better correlation between treatment effects on overall survival and progression-free survival: a literature-based meta-analysis of clinical trials in patients with metastatic colorectal cancer. ORR, OS, PFS
29  2020 Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study. ---
30  2020 Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer. ICERs, OS, PFS, QALYs, WTP
31  2020 Modeling Tumor Evolutionary Dynamics to Predict Clinical Outcomes for Patients with Metastatic Colorectal Cancer: A Retrospective Analysis. LASSO, NLME, OS, PFS
32  2020 Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis. MSI-H
33  2020 Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: Dose and site of metastases matter. LP, MVA, OS, PFS, SBRT, SCST
34  2020 Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial. AEs, OS, QOL
35  2020 Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors. AEs, MTD
36  2020 Practice variation on hospital level in the systemic treatment of metastatic colorectal cancer in The Netherlands: a population-based study. ---
37  2020 Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. HR, ICIs, MSI-H, OS, PFS, RR, TIL, TILs, TMB
38  2020 Predictors of outcome in elderly patients with metastatic colorectal cancer: the final results of a prospective phase II study of bevacizumab in combination with capecitabine as first-line treatment. ORR, OS, PFS
39  2020 Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis. EGFR, PFS
40  2020 Prognostic value of the serum apolipoprotein B to apolipoprotein A-I ratio in metastatic colorectal cancer patients. apoA-I, apoB, CI, HR, PSM, ROC
41  2020 Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib. HR, MPR, OR, PDC, REG
42  2020 Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial. HR, OS
43  2020 Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials? AEs, OS, PFS
44  2020 Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306). Cet-ST, CI, ETS, FOLFIRI, HR, OS
45  2020 Retrospective analysis of the efficacy of cytokine-induced killer cell immunotherapy combined with first-line chemotherapy in patients with metastatic colorectal cancer. CIK, OS, PFS
46  2020 Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme. 5-FU, NPP
47  2020 Selective vascular endothelial growth factor receptor inhibitors provide limited benefits for metastatic colorectal cancer: a meta-analysis. 5-FU, AE, ALP, AST, CR, DCRs, ORRs, OS, PD, PFS, PR, RCTs, SD, TEAEs, VEGFR
48  2020 Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice. OS, PFS
49  2020 The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer. CAP-B, HRQoL, SMM
50  2020 The outcome of primary tumor resection in the unresectable stage IV colorectal cancer patients who received the bevacizumab-containing chemotherapy. BCT, OS, PD, PTR
51  2020 Treatment and outcomes of metastatic colorectal cancer patients in public and private hospitals: Results from the South Australian Metastatic Colorectal Cancer Registry. IRSAD
52  2020 Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG). SoFOG
53  2020 Treatment patterns and direct medical costs of metastatic colorectal cancer patients: a retrospective study of electronic medical records from urban China. ---
54  2020 Treatment patterns for metastatic colorectal cancer in Spain. ---
55  2020 Tumor sidedness and efficacy of first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer: A network meta-analysis. PFS, RAS, RCTs, WT
56  2020 Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival. CRPC, CTCs, HRs, MBC, NSCLC, OS, tdEVs
57  2020 Ubiquitin-Specific Protease 21 Promotes Colorectal Cancer Metastasis by Acting as a Fra-1 Deubiquitinase. AP-1, Fra-1, USP21
58  2020 Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia. ---
59  2020 Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study). CI, EGFR, HR, ORR, OS, PFS, VEGF, WT
60  2019 3'-Deoxy-3'-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies. 18F-FDG, 18F-FLT, CI, OS, PERCIST, PET/CT, PFS, PMD, PMR
61  2019 A case of panitumumab containing chemotherapy causing interstitial lung disease: early recognition and treatment resulting in a good outcome. ILD
62  2019 A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer. FFPE
63  2019 A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis. RCTs
64  2019 A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer. ctDNA
65  2019 A National Survey of Medical Oncologist's Opinions and Perceptions for Managing Rash Among mCRC Patients Treated with Panitumumab. UV
66  2019 A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer. RFA
67  2019 A novel scoring system predicting survival benefits of palliative primary tumor resection for patients with unresectable metastatic colorectal cancer: A retrospective cohort study protocol. CA19-9, CEA, LDH, NLR, OS, PPTR
68  2019 A phase 2 randomised study of veliparib plus FOLFIRIbevacizumab versus placebo plus FOLFIRIbevacizumab in metastatic colorectal cancer. PFS
69  2019 A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer. CI, i.v, SBRT
70  2019 A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada. ---
71  2019 A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer. NGS
72  2019 A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. 5-FU, HR, PDO, PDX
73  2019 A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer. BSC, CI, HR, OS, PFS
74  2019 A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer. FTD, mOS, mPFS, TPI
75  2019 A Trial Protocol of Biweekly TAS-102 and Bevacizumab as Third-Line Chemotherapy for Advanced/Recurrent Colorectal Cancer: A Phase II Multicenter Clinical Trial (The TAS-CC4 Study). OS, PFS, RR
76  2019 A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. CI, HR, OS
77  2019 aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer. aCGH, CNG, OS, PFS, RR
78  2019 Afatinib treatment for her-2 amplified metastatic colorectal cancer based on patient-derived xenograft models and next generation sequencing. NGS, PDX, PFS
79  2019 Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). ASQoP, EORTC, HRQL, TEAEs
80  2019 AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3. AMPK, OS, PFS, SNPs, TR
81  2019 Analysis of response-related endpoints in trials of first-line medical treatment of metastatic colorectal cancer. DCR, ETS, ORR, OS, PFS, RCTs
82  2019 Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients. AF, cfDNA, ctDNA, ddPCR, LOD, NGS, NPA, PPA
83  2019 ANCHOR CRC: a phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BINI), plus cetuximab (CETUX) in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC). BINI, CETUX, ENCO
84  2019 Another Chapter of the Right Versus Left Story: Is Primary Tumor Location a Prognostic Feature in RAS Mutant Metastatic Colorectal Cancer? HR, OS, PTL
85  2019 Apatinib as an optional treatment in metastatic colorectal cancer. CI, NLR, ORR, OS, PFS
86  2019 Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A. BEVA, HR, OS, PFS, RORE, SNPs
87  2019 Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer. CRC, HER2, HERACLES criteria
88  2019 Association between polymorphisms in EGFR and tumor response during cetuximab and oxaliplatin-based combination therapy in metastatic colorectal cancer: Analysis of data from two clinical trials. CI, EGFR, FcgammaR
89  2019 Association of antibiotic exposure with the mortality in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy: A hospital-based retrospective cohort study. PSM
90  2019 Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer. HFSR
91  2019 Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status. dMMR, HT17, MSI
92  2019 Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. MET, OS, PFS
93  2019 Baseline serum lactate dehydrogenase level predicts survival benefit in patients with metastatic colorectal cancer receiving bevacizumab as first-line chemotherapy: a systematic review and meta-analysis of 7 studies and 1,219 patients. HRs, LDH, OS, PFS
94  2019 Bayesian machine learning on CALGB/SWOG 80405 (Alliance) and PEAK data identify a heterogeneous landscape of clinical predictors of overall survival (OS) in different populations of metastatic colorectal cancer (mCRC). OS
95  2019 Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis. CT, OS, PFS
96  2019 Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study. Bmab, OS
97  2019 Bevacizumab treatment in metastatic colorectal carcinoma - an economic perspective. HTA, OS, PFS
98  2019 Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients. OS, PFS
99  2019 Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer. EGFR, MEK, NCCN
100  2019 Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. ---